Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
Pustular and erythrodermic psoriasis are rare and difficult-to-treat conditions. It has recently been shown that interleukin (IL)-17 inhibitors can be very effective among patients with these forms of psoriasis; however, the potential of IL-23 inhibitors is largely unknown. The aim of this multicent...
Main Authors: | Gianluca Avallone, Carlo Alberto Maronese, Giulia Murgia, Carlo Giovanni Carrera, Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo, Silvia Alberti-Violetti, Pietro Quaglino, Simone Ribero, Angelo Valerio Marzano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/4/1662 |
Similar Items
-
Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
by: Lu X, et al.
Published: (2023-07-01) -
Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study
by: Chaochen Wang, et al.
Published: (2023-12-01) -
Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016-09-01) -
Pustular Psoriasis: From Pathophysiology to Treatment
by: Giovanni Genovese, et al.
Published: (2021-11-01) -
Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)